ctDNA and MRI Parameters in Head and Neck Cancer

N/ANot Yet RecruitingNCT06215612

Franziska Eckert50 enrolled

Overview

Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study. In addition to standard of care treatment patients will undergo addiational blood draws and MR imaging studies. Circulating cell free tumor DNA will be analysed in the blood samples. BIological data, imaging data and clinical data (such as patient and tumor characteristics, oncologic outcome, side effects) will be analysed in a biomathematical modelling approach.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Head and Neck Neoplasms Carcinoma, Squamous

Interventions

Blood draw, MRIOTHER

Blood draw, MRI

Eligibility

Sex: ALLMin age: 19 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Squamous cell carcinoma head and neck * Planned primary platinum based radiochemotherapy * ECOG 0-2 Exclusion Criteria: * Palliative therapy intent * Not MR eligible

Outcomes

Primary Outcomes

percentage of patients with 50% decrease in ctDNA

Time frame: 7 weeks after start of radiotherapy

Secondary Outcomes

Completion of all planned MR imagings and blood tests

Time frame: through study completion, an average of 7 weeks

Decrease of tumor volume

Time frame: 7 weeks after start of radiotherapy

Central Contacts

Franziska Eckert, M.D.

CONTACT

+43-1-40400-26920 franziska.eckert@meduniwien.ac.at

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.